Syngene -Clinical Development

Belkins
Syngene is a leading Asian CRO that provides a broad range of discovery, development, manufacturing and clinical development solutions to biopharma companies. Syngene's clinical development services span a broad spectrum of activities including human pharmacology, bioanalytical research, central laboratory, clinical operations, medical writing, medical monitoring, safety management, pharmacovigilance, clinical data management & biostatistics and regulatory services supporting early-phase through late-phase clinical development programs.

C-Suite On Deck

Responsive image

Feature market insights and perspectives from top C-Level executives, elite technology influencers and thought leaders from your company here. This signature initiative has garnered immense support...

Contact Us

Events

Related News

PHARMACY MARKET

TREOSULFAN, A FIRST-IN-CLASS CONDITIONING AGENT, IS LICENSED IN CANADA BY MEDEXUS PHARMACEUTICALS AND MEDAC GMBH

Medexus Pharmaceuticals | July 13, 2021

news image

Medexus Pharmaceuticals Inc. announced today that it has entered into a licensing deal with medac GmbH to commercialize treosulfan, a bifunctional alkylating agent, in Canada. Treosulfan will be sold in Canada as Trecondyv and will be used in conjunction with fludarabine as part of a conditioning regime before allogeneic hematopoietic stem cell transplantation. Medexus will be in charge of selling and promoting the product, while Medac will manufacture and supply it. ...

Read More

EXSCIENTIA TO SCREEN 15,000 DRUGS IN SEARCH FOR CORONAVIRUS TREATMENT

HIT Consultant | April 07, 2020

news image

Exscientia announced a joint transatlantic initiative with Diamond Light Source, the UK’s national synchrotron facility and Calibr, a division of Scripps Research (USA), to screen nearly every known approved and investigational drug against key COVID-19 drug targets to progress compounds that could rapidly become viable drugs for the rapid treatment of the coronavirus. Exscientia has gained access to Calibr’s world’s leading collection of 15,000 clinically-ready molecules, and ...

Read More

MEDICURE ANNOUNCES TERMINATION OF REDS™ PRO MARKETING AND DISTRIBUTION AGREEMENT

Prnewswire | August 20, 2020

news image

Medicure Inc. a pharmaceutical company, today announced the termination of the marketing and distribution agreement with Sensible Medical Innovations Inc. ("Sensible") for the marketing of the ReDSTM Pro ("ReDS Pro") device in the United States. In connection with the termination, Sensible and the Company have entered into a transition agreement which provides additional compensation to Medicure for sales to customer leads provided by Medicure. Medicure continues to hold a 7....

Read More

USA TO DO A CLINICAL TEST OF THE JAPANESE ANTI-FLU DRUG AVIGAN TO TREAT THE PATIENTS SUFFERING FROM CORONAVIRUS

Clout News | April 12, 2020

news image

The number of positive cases of coronavirus are on a rising spree all over the world. The confirmed cases of COVID-19 on a global scale have crossed 1.7 million with the death toll crossing 1,08,000. The most affected country because of coronavirus is the United States of America. With around 5,33,378 positive cases in USA, its death toll has reached more than 20,600 leaving Italy’s death toll behind. According to the reports, USA recorded over 2,000 deaths because of COVID-19. The country...

Read More

PHARMACY MARKET

Medexus Pharmaceuticals | July 13, 2021

news image

TREOSULFAN, A FIRST-IN-CLASS CONDITIONING AGENT, IS LICENSED IN CANADA BY MEDEXUS PHARMACEUTICALS AND MEDAC GMBH

Medexus Pharmaceuticals Inc. announced today that it has entered into a licensing deal with medac GmbH to commercialize treosulfan, a bifunctional alkylating agent, in Canada. Treosulfan will be sold in Canada as Trecondyv and will be used in conjunction with fludarabine as part of a conditioning regime before allogeneic hematopoietic stem cell transplantation. Medexus will be in charge of selling and promoting the product, while Medac will manufacture and supply it. ...

Read More

HIT Consultant | April 07, 2020

news image

EXSCIENTIA TO SCREEN 15,000 DRUGS IN SEARCH FOR CORONAVIRUS TREATMENT

Exscientia announced a joint transatlantic initiative with Diamond Light Source, the UK’s national synchrotron facility and Calibr, a division of Scripps Research (USA), to screen nearly every known approved and investigational drug against key COVID-19 drug targets to progress compounds that could rapidly become viable drugs for the rapid treatment of the coronavirus. Exscientia has gained access to Calibr’s world’s leading collection of 15,000 clinically-ready molecules, and ...

Read More

Prnewswire | August 20, 2020

news image

MEDICURE ANNOUNCES TERMINATION OF REDS™ PRO MARKETING AND DISTRIBUTION AGREEMENT

Medicure Inc. a pharmaceutical company, today announced the termination of the marketing and distribution agreement with Sensible Medical Innovations Inc. ("Sensible") for the marketing of the ReDSTM Pro ("ReDS Pro") device in the United States. In connection with the termination, Sensible and the Company have entered into a transition agreement which provides additional compensation to Medicure for sales to customer leads provided by Medicure. Medicure continues to hold a 7....

Read More

Clout News | April 12, 2020

news image

USA TO DO A CLINICAL TEST OF THE JAPANESE ANTI-FLU DRUG AVIGAN TO TREAT THE PATIENTS SUFFERING FROM CORONAVIRUS

The number of positive cases of coronavirus are on a rising spree all over the world. The confirmed cases of COVID-19 on a global scale have crossed 1.7 million with the death toll crossing 1,08,000. The most affected country because of coronavirus is the United States of America. With around 5,33,378 positive cases in USA, its death toll has reached more than 20,600 leaving Italy’s death toll behind. According to the reports, USA recorded over 2,000 deaths because of COVID-19. The country...

Read More